article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. She further pointed out that 73% of risk sharing agreements have been associated with a positive reimbursement decision.

Marketing 257
article thumbnail

Eli Lilly, Pfizer, Merck among Big Pharma losers in China's latest round of procurement bidding

The Pharma Data

The latest results underscore that large pharma companies are making a “strategic retreat from some of their older drugs,” in China, ICBC International Research analyst Zhang Jialin said, as quoted by Bloomberg; instead, they’re focusing on growing market share for newer medicines. It’s not a completely unforeseen shift, though.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Retail Sales of Plant-Based Foods Surged to $7 Billion in 2020

XTalks

Kyle Gaan, a research analyst at GFI said in the same press release, “2020 was a breakout year for plant-based foods across the store. The growth can also be attributed to the placement of plant-based meat in the meat section, with refrigerated plant-based meat sales growing twice as fast as their frozen counterparts.

Sales 98
article thumbnail

Sanofi offers refunds for Cablivi in novel model for rebates

Pharmaceutical Technology

Dr. James George, a research professor at the University of Oklahoma Health Sciences Center, said Cablivi “adds a new aspect to treatment, the prompt recovery of platelets and prompt resolution of transient neurologic symptoms”. The disorder has a reported annual incidence between 1.5 cases per million in Europe.

Drugs 130
article thumbnail

BioSpace Movers & Shakers, Jan. 1

The Pharma Data

Prior to that, Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector. Zhang will be responsible for all aspects of financial management and work closely with Novotech Holdings’ executive team to support the growth of the business across Asia.

article thumbnail

Novotech Health Holdings Appoints Zidong Zhang as CFO

The Pharma Data

28, 2020 /PRNewswire/ — Novotech Health Holdings (“Novotech Holdings”), the largest biotech specialist contract research organization (CRO) in Asia , today announced the appointment of Zidong Zhang as Chief Financial Officer (CFO) effective 4 January 2021. SHANGHAI and SYDNEY , Dec.

article thumbnail

More Positive Data for Eli Lilly’s Diabetes and Weight Loss Injection Tirzepatide

XTalks

Tirzepatide’s continuing stellar trial results as a weight loss injection have industry analysts putting up big predictions for the drug, particularly as a rival to Novo’s obesity drug Wegovy (tirzepatide is currently only approved for the treatment of type 2 diabetes under the trade name Mounjaro). billion in sales by 2026.